Trials / Completed
CompletedNCT02398682
Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD)
Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) - A Pilot Study to Look at Enhancing Patient Care, Improving Patient Outcomes and Reducing NHS Costs
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,865 (actual)
- Sponsor
- Heart of England NHS Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study pilots an outreach service for Acute kidney injury (AKI) patients, based on electronic alerts. Using the alerts we will contact the primary clinician caring for the patient with AKI in the Intervention group. The study has a control group of patients receiving good standard care, but without Outreach. The aim is to reduce morbidity and mortality in the syndrome, and also to reduce healthcare costs.
Detailed description
Lay summary: About one in six hospital inpatients suffer Acute Kidney Injury (AKI), also called acute renal failure. About a third of patients with AKI die. The large majority of patients with AKI are managed by doctors who are not kidney experts. Effective AKI advice and treatments are available but not currently integrated into routine care. A recent National review of the care of patients who died from AKI showed poor management of many patients. Early diagnosis of AKI can avoid complications, dialysis (which affects the quality of life of patients, and is costly) or death. AKI is diagnosed by a change in a blood test. We have developed computer software to diagnose AKI earlier. It sends a warning or 'Alert' about the test to our team of kidney experts. We will further develop the settings of the Alert system. It needs to send an Alert for the right patients. We will also study the best way to make clinicians pay attention to their patients who are developing AKI. When our expert Outreach team receive an Alert, they will call the doctor or nurse looking after the patient with AKI. We will advise on the best treatment for that patient, to reduce their risk of death, dialysis and other complications. We will do a pilot study in one large hospital, to further develop the system, and check it reduces the risk of death or complications from AKI. We will use this work to develop a larger trial of this new system of care for patients with AKI in different hospitals. This will convince the wider NHS of the need to change, and show how to prevent or reduce AKI. Ultimately we aim to improve patients' lives by reducing avoidable death and illness from AKI , and also save the NHS money.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Rapid diagnosis of AKI cause | The Outreach team will advise on an evidence-based package of care: 1\) Rapidly establish a credible diagnosis of the cause of AKI including: 1. Improved assessment of volume status 2. Standardised use of urine dipstick . 3. Appropriate sepsis investigations. 4. Urgent ultrasound with suspected obstruction. |
| OTHER | Rapid treatment of AKI cause | Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction. |
| OTHER | Stopping 'nephrotoxic' drugs | Cessation of all potentially nephrotoxic drugs. |
| OTHER | Early nephrology followup for stage 3 AKI | A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital. |
| OTHER | Preventing recurrent AKI | Patients with AKI in the Intervention arm will receive information on preventing AKI during the study. |
| OTHER | Good standard care | Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI. |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2017-05-31
- Completion
- 2017-05-31
- First posted
- 2015-03-25
- Last updated
- 2018-02-26
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02398682. Inclusion in this directory is not an endorsement.